Latest News and Press Releases

- Company remains on track to report pivotal data from lead program, ADAIR, in second half 2021 - Novel abuse-deterrent platform technology enables pipeline expansion opportunities across multiple...

- Financial executive bringing over 20 years of experience in accounting, finance and management with a foundation established from big four accounting firm PHILADELPHIA, PA, May 11, 2021 ...

Live video webcast with David Baker, President and CEO of Vallon on Tuesday, May 18, 2021 at 4:15 PM ET PHILADELPHIA, PA, May 07, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ:...

David Baker, President and CEO of Vallon to participate in the virtual Advances in Neuropsychiatry Panel on April 29th at 10:30 AM ET PHILADELPHIA, PA, April 26, 2021 (GLOBE NEWSWIRE) -- Vallon...

- Ongoing ADAIR SEAL study on target for pivotal data readout in second half of 2021- Target NDA filing in Q2 2022 for a potential abuse-deterrent alternative to commercially available IR amphetamines...

- Pivotal data from lead program, ADAIR, expected in second half 2021 - Potential NDA filing for ADAIR in Q2 2022; targeting a ~$9 billion U.S. ADHD market1 - Novel abuse-deterrent platform...

PHILADELPHIA, PA, March 03, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...

- Accomplished executive leader with more than 30 years of experience in finance and operations PHILADELPHIA, PA, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON),...

PHILADELPHIA, PA, Feb. 12, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON) (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...

PHILADELPHIA, PA, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that...